Clinical, electrophysiological, and biochemical markers of peripheral and central nervous system disease in canine globoid cell leukodystrophy (Krabbe's disease). Issue 11 (November 2016)
- Record Type:
- Journal Article
- Title:
- Clinical, electrophysiological, and biochemical markers of peripheral and central nervous system disease in canine globoid cell leukodystrophy (Krabbe's disease). Issue 11 (November 2016)
- Main Title:
- Clinical, electrophysiological, and biochemical markers of peripheral and central nervous system disease in canine globoid cell leukodystrophy (Krabbe's disease)
- Authors:
- Bradbury, Allison M.
Bagel, Jessica H.
Jiang, Xuntian
Swain, Gary P.
Prociuk, Maria L.
Fitzgerald, Caitlin A.
O'Donnell, Patricia A.
Braund, Kyle G.
Ory, Daniel S.
Vite, Charles H. - Other Names:
- Bongarzone Ernesto R. guestEditor.
- Abstract:
- Abstract : Globoid cell leukodystrophy (GLD), or Krabbe's disease, is a debilitating and always fatal pediatric neurodegenerative disease caused by a mutation in the gene encoding the hydrolytic enzyme galactosylceramidase (GALC). In the absence of GALC, progressive loss of myelin and accumulation of a neurotoxic substrate lead to incapacitating loss of motor and cognitive function and death, typically by 2 years of age. Currently, there is no cure. Recent convincing evidence of the therapeutic potential of combining gene and cell therapies in the murine model of GLD has accelerated the requirement for validated markers of disease to evaluate therapeutic efficacy. Here we demonstrate clinically relevant and quantifiable measures of central (CNS) and peripheral (PNS) nervous system disease progression in the naturally occurring canine model of GLD. As measured by brainstem auditory‐evoked response testing, GLD dogs demonstrated a significant increase in I‐V interpeak latency and hearing threshold at all time points. Motor nerve conduction velocities (NCVs) in GLD dogs were significantly lower than normal by 12–16 weeks of age, and sensory NCV was significantly lower than normal by 8–12 weeks of age, serving as a sensitive indicator of peripheral nerve dysfunction. Post‐mortem histological evaluations confirmed neuroimaging and electrodiagnostic assessments and detailed loss of myelin and accumulation of storage product in the CNS and the PNS. Additionally, cerebrospinal fluidAbstract : Globoid cell leukodystrophy (GLD), or Krabbe's disease, is a debilitating and always fatal pediatric neurodegenerative disease caused by a mutation in the gene encoding the hydrolytic enzyme galactosylceramidase (GALC). In the absence of GALC, progressive loss of myelin and accumulation of a neurotoxic substrate lead to incapacitating loss of motor and cognitive function and death, typically by 2 years of age. Currently, there is no cure. Recent convincing evidence of the therapeutic potential of combining gene and cell therapies in the murine model of GLD has accelerated the requirement for validated markers of disease to evaluate therapeutic efficacy. Here we demonstrate clinically relevant and quantifiable measures of central (CNS) and peripheral (PNS) nervous system disease progression in the naturally occurring canine model of GLD. As measured by brainstem auditory‐evoked response testing, GLD dogs demonstrated a significant increase in I‐V interpeak latency and hearing threshold at all time points. Motor nerve conduction velocities (NCVs) in GLD dogs were significantly lower than normal by 12–16 weeks of age, and sensory NCV was significantly lower than normal by 8–12 weeks of age, serving as a sensitive indicator of peripheral nerve dysfunction. Post‐mortem histological evaluations confirmed neuroimaging and electrodiagnostic assessments and detailed loss of myelin and accumulation of storage product in the CNS and the PNS. Additionally, cerebrospinal fluid psychosine concentrations were significantly elevated in GLD dogs, demonstrating potential as a biochemical marker of disease. These data demonstrate that CNS and PNS disease progression can be quantified over time in the canine model of GLD with tools identical to those used to assess human patients. © 2016 Wiley Periodicals, Inc. Abstract : Post‐mortem histological evaluations confirmed neuroimaging and electrodiagnostic assessments and detailed loss of myelin and accumulation of storage product in the CNS and the PNS. … (more)
- Is Part Of:
- Journal of neuroscience research. Volume 94:Issue 11(2016)
- Journal:
- Journal of neuroscience research
- Issue:
- Volume 94:Issue 11(2016)
- Issue Display:
- Volume 94, Issue 11 (2016)
- Year:
- 2016
- Volume:
- 94
- Issue:
- 11
- Issue Sort Value:
- 2016-0094-0011-0000
- Page Start:
- 1007
- Page End:
- 1017
- Publication Date:
- 2016-11
- Subjects:
- Krabbe's disease -- large animal model -- biomarker -- electrophysiological testing -- neuroimaging -- CSF psychosine
Neurobiology -- Periodicals
612 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1097-4547 ↗
http://www3.interscience.wiley.com/cgi-bin/jhome/109668564 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1002/jnr.23838 ↗
- Languages:
- English
- ISSNs:
- 0360-4012
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 5022.090000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 1733.xml